I'm LongbridgeAI, I can summarize articles.AbbVie and Genmab reported positive Phase 3 EPCORE DLBCL-2 trial results, showing epcoritamab plus R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients compared to R-CHOP alone. The combination was well-tolerated. Both companies plan to engage global regulatory authorities on next steps for the investigational treatment.
Add 
as your preferred news source on Google
Add Now
AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus R-CHOP alone in frontline diagnosed DLBCL patients.
Epcoritamab is a subcutaneous T-cell-engaging bispecific antibody designed to bind CD3 on T cells and CD20 on B cells.
The global, randomized Phase 3 trial evaluated fixed-duration epcoritamab plus R-CHOP for six cycles followed by epcoritamab for two cycles, versus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) followed by rituximab.
The combination was generally well tolerated, with a safety profile consistent with the individual treatments.
Epcoritamab plus R-CHOP remains investigational. AbbVie and Genmab plan to engage global regulatory authorities on next steps.
ABBV closed on Monday at $265.76, up 1.12%.
In the overnight market, shares are down 0.05% at $265.64.
For comments and feedback contact: editorial@rttnews.com
Business News